{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:14:28Z","timestamp":1761203668516,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11362"],"award-info":[{"award-number":["24K11362"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11910-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:13:34Z","timestamp":1761203614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between immunity and antimicrobial treatment resistance in patients with Mycobacterium avium complex pulmonary disease: a multicenter observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Akinobu","family":"Matsuura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"11910_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106164","volume":"173","author":"JA Schildkraut","year":"2020","unstructured":"Schildkraut JA, Gallagher J, Morimoto K, Lange C, Haworth C, Floto RA, et al. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respir Med. 2020;173:106164.","journal-title":"Respir Med"},{"issue":"6","key":"11910_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3201\/eid2206.151086","volume":"22","author":"H Namkoong","year":"2016","unstructured":"Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis. 2016;22(6):1116\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"11910_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1513\/AnnalsATS.201303-067OC","volume":"11","author":"K Morimoto","year":"2014","unstructured":"Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1\u20138.","journal-title":"Ann Am Thorac Soc"},{"key":"11910_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00424-2022","author":"K Morimoto","year":"2023","unstructured":"Morimoto K, Iwai K, Yoshiyama T, Ito M, Uesugi F, Asakura T, et al. Epidemiological characteristics of nontuberculous mycobacteriosis and bronchiectasis: comparative study using national mortality statistics from 1970 to 2015 in Japan. ERJ Open Res. 2023. https:\/\/doi.org\/10.1183\/23120541.00424-2022.","journal-title":"ERJ Open Res"},{"key":"11910_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00337-2024","author":"Y Hamaguchi","year":"2025","unstructured":"Hamaguchi Y, Morimoto K, Mitarai S. Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.00337-2024.","journal-title":"ERJ Open Res"},{"issue":"7","key":"11910_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/cid\/cix517","volume":"65","author":"N Kwak","year":"2017","unstructured":"Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(7):1077\u201384.","journal-title":"Clin Infect Dis"},{"key":"11910_CR7","doi-asserted-by":"crossref","unstructured":"American Thoracic Society: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997, 156(2 Pt 2):S1\u201325.","DOI":"10.1164\/ajrccm.156.2.atsstatement"},{"key":"11910_CR8","volume-title":"JSTB guidelines for the diagnosis and treatment of tuberculosis","author":"The Japanese Society for Tuberculosis and Nontuberculous Mycobacteriosis","year":"2024","unstructured":"The Japanese Society for Tuberculosis and Nontuberculous Mycobacteriosis. JSTB guidelines for the diagnosis and treatment of tuberculosis. Tokyo: Nankodo; 2024."},{"key":"11910_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr., Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00535-2020.","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"11910_CR10","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1\u201364.","journal-title":"Thorax"},{"issue":"12","key":"11910_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559\u201369.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"11910_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","volume":"18","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial. Ann Am Thorac Soc. 2021;18(7):1147\u201357.","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"11910_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00812-20","volume":"89","author":"M Shamaei","year":"2021","unstructured":"Shamaei M, Mirsaeidi M. Nontuberculous mycobacteria, macrophages, and host innate immune response. Infect Immun. 2021;89(8):e0081220.","journal-title":"Infect Immun"},{"key":"11910_CR14","doi-asserted-by":"publisher","first-page":"927049","DOI":"10.3389\/fimmu.2022.927049","volume":"13","author":"A Gramegna","year":"2022","unstructured":"Gramegna A, Lombardi A, Lore NI, Amati F, Barone I, Azzara C, et al. Innate and adaptive lymphocytes in non-tuberculous mycobacteria lung disease: a review. Front Immunol. 2022;13:927049.","journal-title":"Front Immunol"},{"issue":"1","key":"11910_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2567.2001.01236.x","volume":"103","author":"HL Collins","year":"2001","unstructured":"Collins HL, Kaufmann SH. The many faces of host responses to tuberculosis. Immunology. 2001;103(1):1\u20139.","journal-title":"Immunology"},{"issue":"1","key":"11910_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12890-024-03207-2","volume":"24","author":"J Koh","year":"2024","unstructured":"Koh J, Kim S, Kim JY, Yim JJ, Kwak N. Immunologic features of nontuberculous mycobacterial pulmonary disease based on spatially resolved whole transcriptomics. BMC Pulm Med. 2024;24(1):392.","journal-title":"BMC Pulm Med"},{"issue":"8","key":"11910_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/cid\/cix996","volume":"66","author":"A Aoki","year":"2018","unstructured":"Aoki A, Sakagami T, Yoshizawa K, Shima K, Toyama M, Tanabe Y, et al. Clinical significance of interferon-gamma neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis. 2018;66(8):1239\u201345.","journal-title":"Clin Infect Dis"},{"key":"11910_CR18","doi-asserted-by":"publisher","first-page":"42004","DOI":"10.1038\/srep42004","volume":"7","author":"CC Shu","year":"2017","unstructured":"Shu CC, Wang JY, Wu MF, Wu CT, Lai HC, Lee LN, et al. Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes. Sci Rep. 2017;7:42004.","journal-title":"Sci Rep"},{"key":"11910_CR19","doi-asserted-by":"crossref","unstructured":"Shu CC, Pan SW, Feng JY, Wang JY, Chan YJ, Yu CJ, Su WJ: The clinical significance of programmed death-1, regulatory t cells and myeloid derived suppressor cells in patients with nontuberculous mycobacteria-lung disease. J Clin Med 2019, 8(5).","DOI":"10.3390\/jcm8050736"},{"key":"11910_CR20","doi-asserted-by":"crossref","unstructured":"Lombardi A, Villa S, Castelli V, Bandera A, Gori A: T-Cell exhaustion in mycobacterium tuberculosis and nontuberculous mycobacteria infection: pathophysiology and therapeutic perspectives. Microorganisms 2021, 9(12).","DOI":"10.3390\/microorganisms9122460"},{"key":"11910_CR21","doi-asserted-by":"publisher","first-page":"1047781","DOI":"10.3389\/fimmu.2022.1047781","volume":"13","author":"CN Ratnatunga","year":"2022","unstructured":"Ratnatunga CN, Tungatt K, Proietti C, Halstrom S, Holt MR, Lutzky VP, et al. Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease. Front Immunol. 2022;13:1047781.","journal-title":"Front Immunol"},{"issue":"1","key":"11910_CR22","first-page":"1","volume":"3","author":"A Kurashima","year":"2013","unstructured":"Kurashima A, Morimoto K, Horibe M, Hoshino Y, Shiraishi Y, Kudoh S. A Method for visual scoring of pulmonary mycobacterium avium complex disease: \u201cNICE scoring system.\u201d J Mycobac Dis. 2013;3(1):1\u20135.","journal-title":"J Mycobac Dis"},{"issue":"4","key":"11910_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.5588\/ijtld.16.0711","volume":"21","author":"K Furuuchi","year":"2017","unstructured":"Furuuchi K, Ito A, Hashimoto T, Kumagai S, Ishida T. Clinical significance of the radiological severity score in Mycobacterium avium complex lung disease patients. Int J Tuberc Lung Dis. 2017;21(4):452\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"48","key":"11910_CR24","doi-asserted-by":"publisher","first-page":"18220","DOI":"10.1074\/jbc.RA119.010676","volume":"294","author":"MG Wulf","year":"2019","unstructured":"Wulf MG, Maguire S, Humbert P, Dai N, Bei Y, Nichols NM, et al. Non-templated addition and template switching by Moloney murine leukemia virus (MMLV)-based reverse transcriptases co-occur and compete with each other. J Biol Chem. 2019;294(48):18220\u201331.","journal-title":"J Biol Chem"},{"key":"11910_CR25","doi-asserted-by":"publisher","first-page":"738056","DOI":"10.3389\/fimmu.2021.738056","volume":"12","author":"PH Wang","year":"2021","unstructured":"Wang PH, Wu MF, Hsu CY, Pan SW, Shu CC, Cheng SL. The trend of TIM3 expression on T cells in patients with nontuberculous mycobacterial lung disease: from immune cell dysfunction to clinical severity. Front Immunol. 2021;12:738056.","journal-title":"Front Immunol"},{"issue":"6","key":"11910_CR26","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","volume":"166","author":"M Singer","year":"2016","unstructured":"Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell. 2016;166(6):1500-1511 e1509.","journal-title":"Cell"},{"issue":"2","key":"11910_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/intimm\/dxh358","volume":"18","author":"S Stark","year":"2006","unstructured":"Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol. 2006;18(2):241\u20137.","journal-title":"Int Immunol"},{"issue":"10","key":"11910_CR28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jiac.2023.06.017","volume":"29","author":"HJ Park","year":"2023","unstructured":"Park HJ, Kim JY, Yim JJ, Kwak N. Prognostic serum biomarkers in non-tuberculous mycobacterial pulmonary disease. J Infect Chemother. 2023;29(10):1005\u20137.","journal-title":"J Infect Chemother"},{"issue":"5","key":"11910_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.5588\/ijtld.12.0811","volume":"17","author":"SD Lawn","year":"2013","unstructured":"Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis. 2013;17(5):636\u201343.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"11910_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u201cT cell exhaustion.\u201d Nat Rev Immunol. 2019;19(11):665\u201374.","journal-title":"Nat Rev Immunol"},{"key":"11910_CR31","doi-asserted-by":"crossref","unstructured":"Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J 2017, 49(3).","DOI":"10.1183\/13993003.00537-2016"},{"issue":"1","key":"11910_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12890-016-0349-3","volume":"17","author":"SJ Kim","year":"2017","unstructured":"Kim SJ, Yoon SH, Choi SM, Lee J, Lee CH, Han SK, et al. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease: a prospective cohort study. BMC Pulm Med. 2017;17(1):5.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"11910_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1378\/chest.128.1.94","volume":"128","author":"WJ Koh","year":"2005","unstructured":"Koh WJ, Kwon OJ, Kim EJ, Lee KS, Ki CS, Kim JW. NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases. Chest. 2005;128(1):94\u2013101.","journal-title":"Chest"},{"key":"11910_CR34","unstructured":"Namkoong H, Omae Y, Asakura T, Ishii M, Suzuki S, Morimoto K, Kawai Y, Emoto K, Oler AJ, Szymanski EP et al: Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease. Eur Respir J 2021, 58(2)."},{"issue":"1","key":"11910_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12931-024-02946-4","volume":"25","author":"Y Park","year":"2024","unstructured":"Park Y, Hong JW, Ahn E, Gee HY, Kang YA. PARK2 as a susceptibility factor for nontuberculous mycobacterial pulmonary disease. Respir Res. 2024;25(1):310.","journal-title":"Respir Res"},{"issue":"2","key":"11910_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1165\/rcmb.2017-0218OC","volume":"58","author":"M Matsuyama","year":"2018","unstructured":"Matsuyama M, Martins AJ, Shallom S, Kamenyeva O, Kashyap A, Sampaio EP, et al. Transcriptional response of respiratory epithelium to nontuberculous Mycobacteria. Am J Respir Cell Mol Biol. 2018;58(2):241\u201352.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"11910_CR37","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3389\/fimmu.2019.02888","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Asif H, Holt GE, Griswold AJ, Campos M, Bejarano P, et al. Mycobacterium abscessus-bronchial epithelial cells cross-talk through type I interferon signaling. Front Immunol. 2019;10:2888.","journal-title":"Front Immunol"},{"issue":"14","key":"11910_CR38","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1182\/blood-2011-03-339705","volume":"118","author":"JW Rowley","year":"2011","unstructured":"Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14):e101-111.","journal-title":"Blood"},{"issue":"12","key":"11910_CR39","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774\u201382.","journal-title":"Cancer Res"},{"issue":"18","key":"11910_CR40","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"11910_CR41","first-page":"e33265","volume":"15","author":"AD Knight","year":"2023","unstructured":"Knight AD, Kacker S. Platelet-rich plasma treatment for chronic respiratory disease. Cureus. 2023;15(1):e33265.","journal-title":"Cureus"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11910-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:13:38Z","timestamp":1761203618000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11910-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11910"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11910-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol adhered to the Declaration of Helsinki and the Japanese Ethics Guidelines for Epidemiological Studies. The study was approved by the ethics committee of Nagoya University (2020\u20130553) and Higashinagoya National Hospital institutional review boards (2\u201318) of the participating institutions. Written informed consent was obtained from study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the following information provide relevant financial activities outside the submitted work. Dr. Shindo reports receiving payment for research grant from Japan Society for the Promotion of Science; receiving payment for lectures from KYORIN Pharmaceutical Co., Ltd., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Gilead Sciences Inc., MSD K.K., GlaxoSmithKline plc., Insmed, Inc., Asahi Kasei Pharma Co., Ltd., and Pfizer Inc.; receiving support for attending meetings and\/or travel from Pfizer Inc.; and participates as a member of the case adjudication committee of GlaxoSmithKline Biologicals SA. Dr. Nakagawa reports receiving payment for lectures from Insmed, Inc., and participating on the Advisory Board of Insmed, Inc.. Dr. Nishikawa reports collaboration research grants from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Nippon Becton Dickinson Co., Ltd., Bristol-Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Zenyaku Kogyo Co., Ltd., Oncolys BioPharma Inc., Debiopharm International SA, Asahi Kasei Pharma Co., Ltd., Sysmex Corporation, FUJIFILM Medical Co., Ltd., SRL, Inc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., ARC Therapies Co., Ltd., Meiji Seika Pharma Co., Ltd., RIKAKEN HOLDINGS Co., Ltd., and Eisai Co., Ltd.; participating on the Advisory Board of ARC Therapies Co., Ltd.; receiving payment for lectures from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Nippon Becton Dickinson Co., Ltd., Amgen Inc., and Bristol-Myers Squibb K.K. Bristol-Myers Squibb K.K.; and stock or stock options from ARC Therapies Co., Ltd. and LTZ Therapeutics Inc.. Dr. Ishii reports research funding from Nippon Boehringer Ingelheim Co., Ltd.; and receiving payment for lectures from AstraZeneca K.K., Insmed, Inc., Nippon Boehringer Ingelheim Co., Ltd., KYORIN Pharmaceutical Co., Ltd., GlaxoSmithKline plc., and Pfizer Inc.. No other authors reported disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1394"}}